Taylor Wessing advised Shield Therapeutics on securing $26 million debt and equity fundraising. Shield Therapeutics plc, a specialty pharmaceutical company listed on AIM, has secured a...
You must be a Standard 1 Year member to access this content.
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, concluded its transformational collaboration agreement with global...
You must be a Standard 1 Year member to access this content.
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, extended an existing convertible debt facility by $10...
You must be a Standard 1 Year member to access this content.
